Clinical trials: Radiotracer
Pulmonary Disease, Chronic Obstructive
Absorption & Elimination of Radiolabelled GSK2269557
GSK2269557 is being developed as an anti-inflammatory agent for the treatment of chronic obstructive pulmonary disease (COPD) and other inflammatory lung diseases such as asthma.
- Trial name
- NCT03315559
- Testing
- [14C]-GSK2269557 IV infusion, GSK2269557 via DPI, [14C]-GSK2269557 oral solution
- Where
- United Kingdom
- Volunteers
- 6 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
Healthy Volunteer
A Study of the Pharmacokinetics, Biodistribution and Dosimetry of Granzyme-B Targeted [Cu-64]-Labeled PET Radiotracers in Adult Healthy Volunteers
This is an exploratory clinical study of copper-64 [Cu-64]-labeled granzyme B (GzmB)-targeted compounds for PET/CT imaging. The goal is to determine how GzmB-Targeted [Cu-64]-labeled compounds are distributed in the body by…
- Trial name
- NCT07774650
- Testing
- Granzyme-B targeted [64Cu]-labeled PET radiotracer
- Where
- United States
- Volunteers
- 12 people, healthy volunteers welcome
- Sponsor
- Ratio Therapeutics, Inc.
Sleep Initiation and Maintenance Disorders
Radiolabel Study In Healthy Volunteers For Insomnia-Targeting Drug
The purpose of this study is to define the absorption, breakdown and excretion of a single dose of radiolabelled SB-649868 and its breakdown products by measuring their concentration in blood, urine and faeces over a 7-10 day…
- Trial name
- NCT00520663
- Testing
- 14C-SB649868
- Where
- United Kingdom
- Volunteers
- 8 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
Infections, Respiratory Tract
A Study to Investigate the Recovery, Excretion and Pharmacokinetics of [14C]-GSK2140944 Administered as a Single Intravenous and Single Oral Dose to Healthy Adult Male Subjects
This is an open-label, non-randomized, two-period, cross-over, mass balance study that will evaluate the recovery, excretion, and pharmacokinetics of a single intravenous (IV) dose of [14C]-GSK2140944 (Period 1) and a single oral…
- Trial name
- NCT02000765
- Testing
- GSK2140944 for Injection, GSK2140944 Capsule
- Where
- United Kingdom
- Volunteers
- 6 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
Type 2 Diabetes Mellitus (T2DM)
A Radiolabeled Mass Balance Study of [14C]-Ertugliflozin (PF04971729, MK-8835) In Healthy Male Participants (MK-8835-038)
This is single dose study of radiolabeled [14C]-ertugliflozin (PF04971729, MK-8835) in healthy male volunteers to study the absorption, distribution, metabolism and elimination of ertugliflozin.
- Trial name
- NCT01127308
- Testing
- Ertugliflozin
- Volunteers
- 6 people, healthy volunteers welcome
- Sponsor
- Merck Sharp & Dohme LLC
Focus of Study: Radiolabel Recovery and Survival of RBCs
Inactivation of Whole Blood With Mirasol
The purpose of this study is to evaluate radiolabeled recovery and survival of autologous red blood cells (RBC), derived from Mirasol-treated fresh whole blood (WB), stored as leukoreduced packed RBC (LR-pRBC), and re-infused in…
- Trial name
- IMPROVEII (NCT01907906)
- Testing
- Mirasol System for Whole Blood
- Where
- 2 sites in United States
- Volunteers
- 29 people, healthy volunteers welcome
- Sponsor
- Terumo BCTbio
Rheumatoid Arthritis
Mass Balance and Metabolic Profiling of [14C]AZD5672 in Healthy Male Volunteers
The purpose of this study is to determine how the body breaks down and excretes the investigational drug, AZD5672.
- Trial name
- NCT00711074
- Testing
- AZD5672
- Where
- United Kingdom
- Volunteers
- 4 people, healthy volunteers welcome
- Sponsor
- AstraZeneca
Community-acquired Infection
GSK2251052 Mass Balance in Healthy Adult Subjects
Approximately 6 healthy male subjects will be administered a single 1500 mg intravenous dose of 14C-GSK2251052 under fasted conditions.
- Trial name
- NCT01475695
- Testing
- 14C GSK2251052
- Where
- Netherlands
- Volunteers
- 6 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
Neuroinflammation
Test Re-Test Reliability of [11C]PF-06809247 as a Novel PET Tacer
This is a study measuring the binding kinetics and test-retest characteristics of a subpharmacological dose of [11C]PF-06809247 Monoacylglycerol lipase (MAGL) Positron Emission Tomography (PET) tracer in healthy adult subjects.
- Trial name
- NCT03100136
- Testing
- [11C]PF-06809247
- Where
- 3 sites in United States
- Volunteers
- 7 people, healthy volunteers welcome
- Sponsor
- Pfizer
Hyperhidrosis
Characterization of Exposure From Topical Administration of [14C] Umeclidinium to Axilla or Palm of Healthy Male Subjects
The purpose of this study is to characterize the pharmacokinetics (PK), safety and tolerability of topically applied umeclidinium following single dose topical administration.
- Trial name
- NCT01934153
- Testing
- [14C]Umeclidinium 18.5 mg
- Where
- Netherlands
- Volunteers
- 18 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
Pharmacokinetics of ASP3662, Displacement of Radiotracer
A Positron Emission Tomography Occupancy Study Using Ligand [11C]AS2471907 and Following Oral Dosing of ASP3662
The purpose of this study is to evaluate a novel PET tracer ([11C]AS2471907), and to use [11C]AS2471907 to assess the level and time-course of enzyme occupancy in the human brain prior to and following single oral dose…
- Conditions
- Pharmacokinetics of ASP3662, Displacement of Radiotracer, Healthy Volunteers
- Trial name
- NCT02194491
- Testing
- [11C]AS2471907, Positron Emission Tomography (PET), ASP3662
- Where
- United States
- Volunteers
- 18 people, healthy volunteers welcome
- Sponsor
- Astellas Pharma Global Development, Inc.
Healthy
Phase I Study to Determine the Absorption, Distribution, Metabolism and Excretion of Esreboxetine
The purpose of the study is to learn more about how esreboxetine is handled by the body i.e. the absorption, metabolism and excretion of esreboxetine.
- Trial name
- ADME (NCT00800956)
- Testing
- [14C]-esreboxetine
- Where
- United States
- Volunteers
- 4 people, healthy volunteers welcome
- Sponsor
- Pfizer
Healthy Volunteers
FBCx (Alpha-CD) Mechanism of Action Trial
To determine the fat losses in stool associated with alpha-CD use in healthy volunteers, as compared to placebo when consumed with a standardized radiolabeled fatty meal.
- Trial name
- FMAT (NCT02999620)
- Testing
- Alpha-cyclodextrin
- Where
- Australia
- Volunteers
- 8 people, healthy volunteers welcome
- Sponsor
- SFI Research
Pulmonary Disease, Chronic Obstructive
To Assess the Excretion Balance and Pharmacokinetics of a Single Oral Dose of [14C]SB-681323 in Healthy Adult Males
SB-681323 is a p38 MAP kinase inhibitor and is currently under development by GlaxoSmithKline. This will be an open label study conducted at one site.
- Trial name
- NCT00564746
- Testing
- A single 10 milligram (50 microcurie) oral dose of [14C]SB-681323
- Where
- United Kingdom
- Volunteers
- 4 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
Pulmonary Disease, Chronic Obstructive
To Assess the Excretion Balance and Pharmacokinetics of a Single Oral Dose of [14C]GW856553 in Healthy Adult Males
This will be an open label study conducted at one site. Six healthy male subjects will be enrolled to ensure at least four fully evaluable subjects.
- Trial name
- NCT00599612
- Testing
- GW856553
- Where
- United Kingdom
- Volunteers
- 6 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
Healthy
A Study To Understand How Radiolabelled PF-04449913 Is Taken Up By The Body, Broken Down And Then Removed From The Body
The study aims to understand, using radiolabelled PF-04449913, how this compound is modified by the body once it is absorbed. The study also aims to understand how much of the compound is broken down and how much leaves the body…
- Trial name
- NCT02110342
- Testing
- [14C] PF-04449913
- Where
- United States
- Volunteers
- 6 people, healthy volunteers welcome
- Sponsor
- Pfizer
Healthy Subjects
A Study to Assess Recovery and Survival of Radiolabeled Apheresis Platelet Components Treated With the INTERCEPT Blood System for Platelets With LED Illuminator.
The objective of this study is to assess the post-infusion recovery and survival of platelets in 100% Plasma treated with INTERCEPT Blood System for Platelets with LED Illuminator and stored for 5 days after apheresis collection.
- Trial name
- NCT06697223
- Testing
- INTERCEPT Blood System for Platelets with LED Illuminator
- Where
- 2 sites in United States
- Volunteers
- 40 people, healthy volunteers welcome
- Sponsor
- Cerus Corporation
Opioid Use Disorder
Single Dose Study of [14C]-IDV184001AN ([14C]-IDV184001) in Healthy Adult Male Participants
The purpose of this open label study is to characterise the absorption, metabolism, excretion, and mass balance of [14C]-IDV184001AN ([14C]-IDV184001) in healthy adult male participants.
- Trial name
- NCT05974046
- Testing
- [14C]IDV184001AN
- Where
- United States
- Volunteers
- 7 people, healthy volunteers welcome
- Sponsor
- Indivior Inc.
Healthy Adult
Evaluation of the Pharmacokinetics, Biodistribution and Radiation Dosimetry of [18F]MODAG-009 Positron Emission Tomography (PET) Radiotracers in Adult Healthy Volunteers
This is an open-label, single-center, phase 1 study to further characterize [18F]MODAG-009 in Healthy Volunteers (HV). Approximately 6 participants will be enrolled in this study.
- Trial name
- NCT07617688
- Testing
- [¹⁸F]MODAG-009 PET Imaging
- Where
- United States
- Volunteers
- 6 people, healthy volunteers welcome
- Sponsor
- MODAG GmbH
Depressive Disorder
A PET Study in Healthy Volunteers
This will be an open label, non-randomised [11C]PHNO PET study using healthy male volunteers. Each volunteer will undergo 4 [11C]PHNO PET scans to allow for further characterisation of this radioligand and examine the effects of…
- Trial name
- NCT01424449
- Testing
- [11C]PHNO, Aripiprazole
- Where
- United Kingdom
- Volunteers
- 7 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline